RFL News and Press, Rafael Holdings Inc. Class B From 11/03/21

Kahn Brothers’ 13F portfolio value increased from $698M to $710M this quarter. Pfizer, VOXX International, and ViewRay were increased substantially during the quarter. The portfolio continues to be very concentrated with the top five positions accounting for ~44% of the 13F...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The resilient U.S. stock market racked up another round of record highs on Friday, as investors looked past disappointing quarterly results f...

Gainers: G Medical Innovations (NASDAQ:GMVD) +15%, Accuray (NASDAQ:ARAY) +14%, Xeris Biopharma (NASDAQ:XERS) +9%, DURECT (NASDAQ:DRRX) +9%, Ocugen (NASDAQ:OCGN) +7%. Losers: CareDx (NASDAQ:CDNA) -25%, 4D Molecular Therapeutics (NASDAQ:FDMT) -2...

Gainers: HCW Biologics (NASDAQ:HCWB) +132%. InflaRx (NASDAQ:IFRX) +45%. Digital Brands Group (NASDAQ:DBGI) +43%. Lucid Group (NASDAQ:LCID) +38%. Wolfspeed (NASDAQ:WOLF) +32%. LendingClub Corporation (NYSE:LC) +32%. Overstock (NASDAQ:OSTK) +25%. Impinj (NASDAQ:PI) +24%. Triterras (NASDAQ:TRIT)...

Shares of Rafael Holdings (NYSE: RFL) are tanking after its subsidiary Rafael Pharmaceuticals reported disastrous news for its experimental new cancer therapy. Investors caught off guard by a pair of clinical trial failures have hammered the stock 80% lower as of 10:45 a.m. EDT on T...

Gainers: HCW Biologics HCWB +115%, InflaRx IFRX +40%, Inspira Technologies Oxy (NASDAQ:IINN) +37%, Community Health Systems (NYSE:CYH) +16%, Invacare (NYSE:IVC) +11%. Losers: Rafael RFL -80%, DBV Technologies (NASDAQ:DBVT) -13%, Alny...

Rafael Holdings (NYSE:RFL) -76% after devimistat fails main goal in late-stage adenocarcinoma trial. Siyata Mobile (NASDAQ:SYTA) -22%. Futu Holdings (NASDAQ:FUTU) -20% after China warns on unlicensed online brokerages. UP Fintech Holding (NASDAQ:TIGR) -18% after ...

CRANBURY, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, today announced that the AVENGER 500 Phase 3 clinical trial evaluating ...

Rafael Holdings (NYSE:RFL) shares plummeted more than 70% premarket after the company's CPI-613 (devimistat) failed to meet the primary endpoint of significant improvement in overall survival in patients with metastatic adenocarcinoma of the pancreas in a late-stage t...

Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival Independent Data Monitoring Committee Recommended the Phase 3 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia Be Stopped Due to Lack of Efficacy ...